SUVEN2024-10-012024-12-31 SUVEN2024-10-012024-12-31 SUVEN2024-10-012024-12-31in-bse-fin:OneOperatingExpenses01Member SUVEN2024-10-012024-12-31in-bse-fin:OneOperatingExpenses02Member SUVEN2024-10-012024-12-31in-bse-fin:FourOperatingExpenses01Member SUVEN2024-10-012024-12-31in-bse-fin:FourOperatingExpenses02Member SUVEN2024-12-31 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 530239 SUVEN NOTLISTED Suven Life Sciences Limited Equity 2024-04-01 2025-03-31 2025-01-24 2025-01-16 INR Lakhs Third quarter 15:15:00 15:50:00 2025-01-24 2025-01-24 Not applicable Single segment The Company has only one business segment, i.e. Research & Development and does not operate in any other segments. Hence, segment reporting as per IND AS 108 (Operating Segment) is not presented 2024-10-01 2024-12-31 Audited Consolidated 16099000.00 16305000.00 32404000.00 0.00 0.00 0.00 48658000.00 79000.00 15335000.00 359498000.00 423570000.00 -391166000.00 0.00 -391166000.00 0.00 0.00 0.00 0.00 -391166000.00 0.00 0.00 0.00 0.00 -391166000.00 -45000.00 -391211000.00 0.00 0.00 0.00 0.00 218074000.00 1 -1.79 -1.79 0.00 0.00 -1.79 -1.79 1) The above financial results of the Company have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on January 24, 2025. The results for the quarter ended December 31, 2024 has been reviewed by our statutory auditors. 2) The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder. 3) The consolidated financial results include the results of the wholly Owned Subsidiary, Suven Neurosciences, Inc. 4) The Company has only one business segment i.e. Research & Development and does not operate in any other segments. Hence, segment reporting as per IND AS 108 (Operating Segment) is not presented. 5) The Company has alloted 7,26,91,239 equity shares amounting to Rs. 39,980.18 lakhs through rights issue on November 16,2022. Summary of Utilisation of Proceeds of Rights issue Particulars Amount Rs. In lakhs Amount Raised through Rights Issue of Shares 39,980.18 Less: Rights Issue Expenses (280.00) Less: Amount Utilised (37,490.74) Balance Amount 2,209.44 6) The Company implemented SLSL Employee Stock Option Scheme 2020 (ESOP) for eligible employees, which provides for the issuance of 10,00,000 options, each option convertible into one equity share. Out of these, 6,20,000 options were granted by the Nomination and Remuneration Committee on May 6, 2024. For the period ended December 31, 2024, the employee benefit expense includes a charge of Rs. 75.37 Lakhs in respect of equity-settled share-based payment transactions, in accordance with Ind AS 102 - Share-based Payment. 7) The corresponding previous period figures have been regrouped reclassified where ever necessary. Single segment 2024-04-01 2024-12-31 Unaudited Consolidated 51888000.00 96744000.00 148632000.00 0.00 0.00 0.00 147588000.00 466000.00 44750000.00 1123829000.00 1316633000.00 -1168001000.00 0.00 -1168001000.00 0.00 0.00 0.00 0.00 -1168001000.00 0.00 0.00 0.00 0.00 -1168001000.00 -135000.00 -1168136000.00 0.00 0.00 0.00 0.00 218074000.00 1 -5.36 -5.36 0.00 0.00 -5.36 -5.36 Other Expenses 18166000.00 R & D Expenses 341332000.00 Other Expenses 57461000.00 R & D Expenses 1066368000.00 -45000.00 -135000.00 0.00 0.00 0.00 0.00